Pancreatic endocrine tumors (PETs) have long fascinated clini-cians, because some can
release biologically active hormones that cause distinct syndromes and provide important …

Pancreatic neuroendocrine tumors (PNETs) are rare neoplasms representing< 5% of all
pancreatic malignancies with an estimated incidence of 1–1.5 cases/100,000. PNETs are …

Pancreatic endocrine tumors (PET's) can be divided on a clinical and pathologic basis into
ten classes [insulinomas, gastrinomas (Zollinger-Ellison syndrome), VIPomas (Verner …

Pancreatic endocrine tumors (PETs) have long fascinated clinicians and investigators
despite their relative rarity. Their clinical presentation varies depending on whether the …

The pathobiology of neuroendocrine tumors (NETs) is hampered by the lack of scientific
tools that define their mechanisms of secretion, proliferation, and metastasis; and, currently …

Pancreatic neuroendocrine tumours (PETs) are the second most frequent pancreatic
neoplasms. Their poor chemosensitivity, high rate of metastatic disease and relatively long …

Gastrinomas are neuroendocrine neoplasms, usually located in the duodenum or pancreas,
that secrete gastrin and cause a clinical syndrome known as Zollinger-Ellison syndrome …

This review focuses on discussing the main modifications of the recently published 2017
WHO Classification of Neoplasms of the Neuroendocrine Pancreas (panNEN). Recent …

This ENETS guidance paper aims to provide practical advice to clinicians for the diagnosis,
treatment and follow-up of functioning syndromes in pancreatic neuroendocrine tumours …

Opinion statement Pancreatic neuroendocrine tumors (PanNETs) are a diverse group of rare
neoplasms. Commonly referred to as islet cell tumors, PanNETs are classified as functional …